Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. This course reviews a number of recently reported trials looking at potential treatments options with: Multiple Kinase Inhibitors, Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy (PRRT).